Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
News and Views
Nature Biotechnology 26, 1345–1346 (1 December 2008) | doi:10.1038/nbt1208-1345
Microfluidics closes in on point-of-care assays
Abstract
Routine assessment of biomarkers promises to transform many areas of medicine, from clinical trials, which will benefit from biomarker-based segmentation of patient populations, to the diagnosis and treatment of complex disease. To add real value, biomarkers must be measurable by clinicians and provide useful new information.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
